Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.

Literature DB >> 9624503

Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.

G A Pankuch¹, M R Jacobs, P C Appelbaum.

Abstract

Trovafloxacin pneumococcal and staphylococcal postantibiotic effects (PAEs) were 0.7 to 1.8 and 0.7 to 2.4 h, respectively. For Escherichia coli and Pseudomonas aeruginosa, PAEs were 2.4 to 4.4 h. Pneumococcal and staphylococcal postantibiotic sub-MIC effects (PA-SMEs) (0.4 times the MIC) were 2.3 to 3.7 and 2.4 to > 9.2 h, respectively, and E. coli PA-SMEs (0.3 times the MIC) were 6.8 to > 12.0 h. For one P. aeruginosa strain, the PA-SME (0.4 times the MIC) was > 10 h; in the other, rapid bactericidal activity precluded measurement.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1998 PMID： 9624503 PMCID： PMC105631

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. Postantibiotic effect of trovafloxacin on Pseudomonas aeruginosa.

Authors: F J Boswell; J M Andrews; R Wise
Journal: J Antimicrob Chemother Date: 1997-06 Impact factor: 5.790

2. Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.

Authors: G A Pankuch; M R Jacobs; P C Appelbaum
Journal: J Antimicrob Chemother Date: 1995-01 Impact factor: 5.790

3. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors: G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal: Antimicrob Agents Chemother Date: 1993-02 Impact factor: 5.191

Review 4. The post-antibiotic effect.

Authors: F M MacKenzie; I M Gould
Journal: J Antimicrob Chemother Date: 1993-10 Impact factor: 5.790

Review 5. The post-antibiotic sub-MIC effect in vitro and in vivo.

Authors: O Cars; I Odenholt-Tornqvist
Journal: J Antimicrob Chemother Date: 1993-05 Impact factor: 5.790

6. In vitro activity of the new fluoroquinolone CP-99,219.

Authors: H C Neu; N X Chin
Journal: Antimicrob Agents Chemother Date: 1994-11 Impact factor: 5.191

7. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

Authors: I Odenholt-Tornqvist
Journal: J Antimicrob Chemother Date: 1993-06 Impact factor: 5.790

8. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.

Authors: R Teng; S C Harris; D E Nix; J J Schentag; G Foulds; T E Liston
Journal: J Antimicrob Chemother Date: 1995-08 Impact factor: 5.790

Review 9. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens.

Authors: W Craig
Journal: Eur J Clin Microbiol Infect Dis Date: 1993 Impact factor: 3.267

10. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors: I Odenholt-Tornqvist; E Löwdin; O Cars
Journal: Antimicrob Agents Chemother Date: 1992-09 Impact factor: 5.191

3 in total

1. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.

Authors: L E Stearne; C Kooi; W H Goessens; I A Bakker-Woudenberg; I C Gyssens
Journal: Antimicrob Agents Chemother Date: 2001-01 Impact factor: 5.191

2. Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.

Authors: G A Pankuch; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1998-11 Impact factor: 5.191

3. Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.

Authors: Inga Odenholt; Elisabeth Löwdin; Otto Cars
Journal: Antimicrob Agents Chemother Date: 2003-10 Impact factor: 5.191

3 in total